N. Rath

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

S. Vermeire, G. Rogler, R. Panaccione, 2017, Gut.

Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month through <6 Years with Gastro-Oesophageal Reflux Disease

Kim G. Adcock, J. Kierkuś, R. Ward, 2011, Clinical pharmacokinetics.

Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro‐oesophageal reflux disease and a history of erosive oesophagitis

G. Comer, D. Riff, H. Schwartz, 2007, Alimentary pharmacology & therapeutics.

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].

E. Peeva, S. Danese, K. Hung, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A Multicenter, Randomized, Open‐Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease

M. Katz, G. Kearns, R. Ward, 2011, Journal of clinical pharmacology.

Pharmacodynamics and Safety of Pantoprazole in Neonates, Preterm Infants, and Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease

J. Kierkuś, Caifeng Fu, G. Comer, 2011, Digestive Diseases and Sciences.

Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)

R. Ward, G. Comer, D. Stewart, 2010, European Journal of Clinical Pharmacology.

Clinical Results From a Randomized, Double-Blind, Dose-Ranging Study of Pantoprazole in Children Aged 1 Through 5 Years With Symptomatic Histologic or Erosive Esophagitis

R. Baker, G. Comer, J. Tung, 2010, Clinical pediatrics.

Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study

Dean M. Messing, S. Tarabar, K. Page, 2020, Clinical pharmacology in drug development.

Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are antitumour necrosis factor inadequate responders

S. Vermeire, G. Rogler, R. Panaccione, 2016 .

764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders

S. Vermeire, G. Rogler, R. Panaccione, 2016 .